Labiotech.eu

Interview 23 Jan 2023

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

January 23, 2023 - 1 minutemin - By Jim Cornall

News and Trends 20 Jan 2023

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics

The guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps. We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL. This week’s podcast […]

January 20, 2023

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 20 Jan 2023

Aldevron launches type-V CRISPR Nuclease

Aldevron, which develops and manufactures plasmid DNA, RNA and proteins for the biotech industry, has launched Eureca-V Nuclease, the wild-type MAD7 CRISPR Type-V nuclease, licensed from Inscripta, at Research Grade, with GMP to follow.   Aldevron’s launch at Advanced Therapies Week of Eureca-V Nuclease expands the toolkit of available CRISPR nucleases for therapeutic, diagnostic, and agricultural […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

The magical microbiome

By Brittany Niccum and Han Wei Now that we are past the holiday season and time when we might have over-indulged on rich foods, many of us are seeing how we can help our bodies bounce back. Science can help. Every environment – organic or inorganic – has a myriad of microorganisms living on the […]

January 20, 2023 - 6 minutesmins - By External Contributor

In Depth 20 Jan 2023

The future of single-cell microfluidics in cell engineering

By Richard Hammond, chief technical officer at Sphere Fluidics Single-cell microfluidic-based techniques continue to be a key enabling technology for cell engineering as they allow true single-cell level working, with the associated precision of measurement and control of environment, and a high level of automation, enabling the speed and scale necessary to process and search […]

January 20, 2023 - 3 minutesmins - By External Contributor

glioblastoma oncolytic virus transgene 2

News and Trends 20 Jan 2023

New drug could replace current standard for treating brain cancer

Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […]

January 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Brenus Pharma and InSphero AG have received a €1.5 million grant for the collaborative project “STC-1010: A First-in-Class Allogeneic Cell Vaccine Against Cancer,” which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer. Funding was provided by the Eurostars fund, a support mechanism for small and medium-sized enterprises under […]

January 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Netherlands Cancer Institute to use Proscia platform

Proscia, a provider of digital and computational pathology solutions, has announced that the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centers in Europe, will deploy its Concentriq Dx platform. NKI is transitioning to Proscia’s Concentriq Dx to expand its digital pathology practice, so its pathologists can deliver personalized diagnoses that better […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Cloned maggot enzyme wound treatment moves closer to reality

Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. Debridement, the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal. […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 19 Jan 2023

Avacta completes fourth dose escalation in tumor study

Avacta Group plc says that AVA6000 continues to show a favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumor biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumor tissue. This confirms the tumor targeting potential […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

GPCR Therapeutics launches multiple myeloma trial

GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics

Aldevron launches type-V CRISPR Nuclease

The magical microbiome

The future of single-cell microfluidics in cell engineering

New drug could replace current standard for treating brain cancer

DeuterOncology closes financing round to start lung cancer study

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Netherlands Cancer Institute to use Proscia platform

Cloned maggot enzyme wound treatment moves closer to reality

Avacta completes fourth dose escalation in tumor study

GPCR Therapeutics launches multiple myeloma trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!